C. Smith

TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.

TL;DR: Early, sustained suppression of HCV replication portends an SVR, and cessation of treatment may be contemplated in patients without a > or = 2 log10 reduction in HCV RNA after 12 weeks.

TL;DR: Once‐weekly PEG(40kd) IFN α‐2a was associated with a higher number of sustained virological responses compared with IFNalpha 3 times weekly in patients with chronic hepatitis C, but had a similar safety profile.

TL;DR: PEG‐IFN alfa‐2b plus weight‐based RBV is more effective than flat‐dose RBV, particularly in genotype 1 patients, providing equivalent efficacy across all weight groups, and RBV 1400 mg/day is appropriate for patients 105 to 125 kg.

TL;DR: Survival data from 379 patients with chronic hepatitis B were analyzed to determine life expectancy for the patient from the time of first contact, and a multivariate analysis found age of 40 years or more, total bilirubin level of 1.5 mg/dLor more, ascites, and spider nevi to be factors that identified patients at a higher risk of death.